Case-Control Study of Inflammatory Breast Cancer in North Africa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00793390|
Recruitment Status : Completed
First Posted : November 19, 2008
Last Update Posted : November 8, 2017
- Inflammatory breast cancer (IBC) is a rare, poorly understood and particularly aggressive form of breast cancer.
- Three characteristics of IBC tumors their rapid progression, their extensive formation of new blood vessels, and the fact that these characteristics are present from the inception of the tumor make it an ideal model for studying factors associated with tumor aggressiveness.
- This study is a collaboration among several institutions in the United States and North Africa that have extensive epidemiological experience and experience with IBC.
- To understand what causes certain types of breast conditions, including IBC.
- Women 18 years of age and older with IBC and non-IBC and healthy women volunteers are eligible. Women who have had a previous diagnosis of any kind of breast cancer are excluded.
- Participants complete a questionnaire providing information about their background, including medical and reproductive history, family health history and lifestyle habits and undergo the following additional procedures:
- Height, weight, hip and chest measurements.
- Saliva sample collection to measure biological factors that may be related to breast conditions.
- Breast examination and, if permission is given, photographs of affected breast.
- Analysis of biopsied tissue for genetic and biochemical factors.
|Condition or disease|
|Inflammatory Breast Cancer|
|Study Type :||Observational|
|Estimated Enrollment :||1200 participants|
|Official Title:||A Case-Control Study of Inflammatory Breast Cancer in North Africa|
|Study Start Date :||November 17, 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00793390
|National Cancer Institute-Cairo|
|Gharbia Cancer Society|
|Tanta Cancer Center|
|Ibn Rochd Oncology Center|
|Marrakech University Hospital|
|Institut Salah Azaiz|
|Principal Investigator:||Catherine Schairer, Ph.D.||National Cancer Institute (NCI)|